Clinical Trial Update: A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the effect of Canagliflozin (JNJ-28431754) on post-meal glucose in adults with Type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Canagliflozin (canagliflozin)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED